Related Experiment Video

Updated: Jul 18, 2026

Development of an Algorithm to Perform a Comprehensive Study of Autonomic Dysreflexia in Animals with High Spinal Cord Injury Using a Telemetry Device
06:51

Development of an Algorithm to Perform a Comprehensive Study of Autonomic Dysreflexia in Animals with High Spinal Cord Injury Using a Telemetry Device

Published on: July 29, 2016

AICD treatment in 2004--state of the art

Thomas Budde1

  • 1Department of Internal Medicine/Cardiology, Alfried Krupp Hospital, Alfried Krupp Str. 21, 45117 Essen, Germany. budde.thomas@krupp-krankenhaus.de

European Journal of Medical Research
|November 17, 2006
PubMed

Insights

The automatic implantable cardioverter-defibrillator ((A)ICD) effectively treats life-threatening arrhythmias, offering crucial prevention for sudden cardiac death in high-risk patients. Studies confirm its benefit in specific heart conditions, improving patient outcomes beyond medication alone.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Preventive Medicine

Background:

  • Medications offer insufficient primary and secondary prevention of sudden cardiac death (SCD).
  • Life-threatening arrhythmias like ventricular fibrillation/flutter and ventricular tachycardia require effective termination.
  • Identifying and managing patients at risk for SCD is critical.

Purpose of the Study:

  • To evaluate the prophylactic role of (automatic) implantable cardioverter-defibrillator ((A)ICD) therapy in various risk groups for sudden cardiac death.
  • To determine patient populations who benefit from (A)ICD implantation for arrhythmia management.
  • To clarify the indications and contraindications for (A)ICD use in cardiac conditions.

Main Methods:

  • Review of landmark clinical trials (e.g., CABG patch, MADIT, MADIT II, MUSTT, DINAMIT, CAT AMIOVIRT, DEFINITE, COMPANION, SCD-HeFT) examining prophylactic (A)ICD indications.
  • Analysis of patient subgroups, including those with post-myocardial infarction status and heart failure.
  • Assessment of (A)ICD efficacy in conjunction with cardiac resynchronization therapy.

Main Results:

  • Patients with chronic myocardial infarction and impaired left ventricular function or non-sustained ventricular tachycardia benefit from (A)ICD therapy.
  • Individuals with moderate to severe heart failure show improved outcomes with (A)ICD implantation, potentially combined with cardiac resynchronization therapy.
  • Divergent data exists for dilated cardiomyopathy; (A)ICD is not indicated in acute myocardial infarction or during elective bypass surgery.

Conclusions:

  • The (automatic) implantable cardioverter-defibrillator ((A)ICD) is a reliable method for terminating life-threatening arrhythmias and preventing sudden cardiac death in selected high-risk patients.
  • Evidence supports prophylactic (A)ICD use in specific post-myocardial infarction and heart failure populations.
  • (A)ICD implantation is contraindicated in acute myocardial infarction and elective bypass surgery settings.

More Related Videos

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Standards of Care II01:19

Standards of Care II

Nurses bear specific legal responsibilities under several federal statutes, including:
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.